Calls › NKE › Oct 14, 2026

NKE Lean bearish NIKE, Inc. · Consumer Cyclical

Value trap — for now.

Published Oct 14, 2026 · Horizon 3-6 months Audited

Edge4/10

Evidence7/10

Entry (close)

$35.33 2026-10-13

Since publish

+5.2% to 2026-10-28

vs SPY

+5.9%

3-month verdict

Closes 2027-01-12

Thesis

NKE is a value trap at current prices: headline trailing P/E of ~16.6x is flattered by a one-time IEEPA tariff recovery ($0.52 of Q4 FY26 EPS), so the clean trailing multiple is ~22x and forward is ~20x on a $1.80 FY27 EPS estimate that is still being revised down (one series already at $1.61). The Elliott Hill turnaround is fragmenting — North America wholesale and running are improving, but China (-26% cN), Digital (-13%), and Direct (-9%) are still deteriorating, and FY27 guidance implies continued shrinkage rather than stabilization. The dividend (~4.5% yield, ~90% payout on FY27 consensus) is a floor but consumes most FCF, limiting buybacks.

Bull case

North America grew +2% with wholesale stabilizing and running growing double-digits for five straight quarters (~+$1B) — the core franchise is healing where it matters most. Tariff relief is a genuine recurring margin tailwind plus refund cash with interest. A ~4.5% dividend yield, $9B cash, and the world's #1 athletic brand provide a floor; if China merely stops deteriorating, the FY28 recovery consensus ($2.40 EPS) makes $35 look like 14.5x FY28 — clearly cheap. Sentiment and positioning are already washed out.

Bear case

The turnaround timeline keeps extending: FY27 guided to shrink high-single-digits, China -26% with no bottom, Direct/Digital in freefall, $1B more restructuring through FY2031, and estimates still being cut. Clean earnings are ~$1.58, so the stock is ~22x clean trailing for negative growth — not distressed. Share loss to On/Hoka/Adidas/Anta is structural, the dividend consumes ~90% of FY27 consensus EPS leaving no buyback support, and FY28's assumed 9.5% growth rebound is the most fragile number in the model. Technicals show a slow bleed, not capitulation — no contrarian entry signal.

What would change our mind

FY27 EPS consensus stabilizes or turns positive for 2+ consecutive months
Greater China decline narrows to low-single-digits or better in Q2/Q3 FY27
Wholesale order book inflects positive with improving full-price realization
If the stock falls toward high-20s while estimates hold ~$1.80, the risk/reward flips and this bearish-lean thesis weakens
Inventory begins declining meaningfully while gross margin (ex-refund) expands

**Nike EPS growth shows a business still shrinking.** YoY diluted EPS growth has turned sharply negative across recent fiscal years, supporting the thesis that NKE's low headline P/E masks deteriorating earnings power.

Since publication vs SPY · closed horizons are frozen

1 weekfinal

+8.7%

+7.2% raw · miss

1 monthrunning

+5.9%

+5.2% raw

3 monthsrunning

+5.9%

+5.2% raw

6 monthsrunning

+5.9%

+5.2% raw

The full research everything the view rests on

Direct answer to the question asked

NKE's decline is fundamental, not sentiment: FY27 revenue is guided to a high-single-digit decline, Greater China fell 26% cN in Q1 FY27, and EPS estimates are still being cut. The stock only looks cheap on headline trailing earnings (~16.6x), which include a $0.52 one-time tariff-refund benefit — on clean ~$1.58 FY26 EPS it trades near 22x trailing / ~20x forward for a shrinking business. With no capitulation signal in technicals and estimates still falling, there is no asymmetric edge at $35.

Where the edge would come from

What the price assumes

At ~20x forward on $1.80 FY27 EPS, the market prices in continued revenue decline in FY27 but a return to ~9.5% revenue growth and ~33% EPS growth in FY28 — i.e., that FY27 is the trough. The current price does not assume a turnaround success; it assumes the bleeding stops by FY28.

Why the market may be wrong

Consensus FY28 growth of 9.5% looks heroic given China has shown no bottom, share loss is structural (Nike's global footwear share fell ~3pp to 22.9% in 2025, third consecutive decline), and Nike is over-indexed to lifestyle footwear, the shrinking segment. If China deterioration forces another guidance cut at the December or March earnings, the FY28 recovery narrative collapses and a 'cheap' stock de-rates further. Conversely, the market may be underpricing the tariff-refund cash tailwind and the NA wholesale inflection if China merely stabilizes.

The one thing to watch

The variable to watch is not revenue or China — it's clean EPS: headline FY26 EPS of $2.10 contains a ~$0.52 one-time tariff refund, so every 'NKE is cheap vs. history' argument using trailing earnings is off by ~30%; on ~$1.58 underlying EPS the stock is ~22x trailing for a company guiding to shrink high-single-digits, which means the current price already embeds the FY28 recovery the data doesn't yet support.

Key evidence (8)

FY revenue $51.4B (FY24) → $46.3B (FY25) → $46.4B (FY26); diluted EPS $3.73 → $2.16 → $2.10 [SEC 10-K, T1]
Q4 FY26 EPS $0.72 included $0.52 one-time IEEPA tariff-recovery benefit; gross margin 49.2% included ~900bp refund benefit [Q4 FY26 release, T1]
Q1 FY27 (reported 10/1/26): revenue $11.2B, -4% reported/-5% cN, missed $11.32B consensus; Greater China -26% cN; EMEA -5%; Digital -13%; NA +2% [company release/Reuters, T2/T4]
FY27 guidance: high-single-digit revenue decline vs. consensus near flat; new 'Pace' restructuring up to $1B pretax charges through FY2031 [Q1 FY27 release/transcript]
FY27 EPS consensus cut ~$2.00 → $1.80 (one series to $1.61 post-earnings); FY28 cut $2.70 → $2.40 [consensus aggregators, T3/T4]
FY26 operating cash flow only $2.87B including ~$0.3B non-recurring tariff recoveries; cash ~$9.0B; inventory $7.5B flat YoY [10-K, T1]
Nike global athletic-footwear share fell ~3pp to 22.9% in 2025, third consecutive annual decline; Adidas rose to ~12.2%; On guiding low-20% cN growth at 65% gross margin [Euromonitor-cited reporting, T2]
Stock -45.8% over 1y, -49% below 52w high; 20d realized vol at 9th percentile, RSI 43, volume 0.6x average — slow bleed, no capitulation [market data, 2026-10-13]

Catalysts and risks

Catalysts

Q2 FY27 earnings (~late December 2026): China trajectory and any FY27 guidance revision
Q3 FY27 earnings (~March 2027): first evidence for/against FY28 recovery consensus
Wholesale order book / futures commentary and full-price sell-through data
China stimulus or consumer data affecting Greater China demand
Tariff refund cash receipts and final resolution of liquidated-entry appeals
Potential further estimate revisions on FY28 $2.40 consensus

Risks

China continues deteriorating beyond -26%, forcing another guidance cut
FY28 recovery consensus proves optimistic, triggering further de-rating
Estimate cuts continue — falling forward EPS mechanically raises the effective multiple
Dividend sustainability questions if FCF stays ~$3B while payout is ~90%
Competitive share loss accelerates in running, Nike's one improving category
Dead-money risk: slow bleed without capitulation can persist for quarters

What to watch

Clean (ex-tariff-refund) EPS trajectory, not headline
FY27/FY28 consensus revision direction week over week
Greater China currency-neutral growth each quarter
Nike Direct/Digital trends vs. wholesale divergence
Operating cash flow and free-cash-flow coverage of the dividend
Volume/capitulation signature: a high-volume washout would mark a better entry than the current low-volatility bleed

Market snapshot when the call was made 2026-10-13

Price

Return 1w	+2.1%
Return 1m	-4.6%
Return 3m	-17.4%
Return 6m	-20.1%
Return 1y	-45.8%
From 52-week high	-49.3%
Realized vol, 20d	23.8%
SPY 3m / 1y	+3.1% / +19.1%
QQQ 3m / 1y	+3.6% / +26.1%

Technicals

NKE technicals as of 2026-10-13: last close $35.33; 20d SMA 35.37 (bearish); 50d SMA 37.87; 12d EMA 35.12; 26d EMA 35.97; RSI 14 43.5 (balanced); 20d vol 23.3%; volume x0.6 vs 20d avg

Sources (31 · T1 = primary filings)

Earlier and later calls on NKE

Sep 29, 2026No — not yet, and earnings is the test.No clear edgeview changed

Want a fresh look at NKE, or another name?

Queue a new deep-research run. Published to the feed when done.

Automated research opinion, published as-is on Oct 14, 2026. Not personalised advice. Figures use end-of-day closes.